CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

BCMA-Directed bb2121 Highly Effective for Myeloma

December 10th 2017

Treatment with the BCMA-directed CAR T-cell therapy bb2121 induced complete remissions for 56% of patients with relapsed/refractory multiple myeloma.

Case Study 2: Options for Biochemically Relapsed MM

December 8th 2017

Case Study 2: An Elderly Patient With Multiple Myeloma

December 8th 2017

Case Study 1: The Value of KRd in Multiple Myeloma

December 8th 2017

Case Study 1: Treating MM After RVd and Transplant

December 8th 2017

Case Study 1: Follow-Up Strategies for Multiple Myeloma

December 8th 2017

Case Study 1: A Diagnosis of Stage II Multiple Myeloma

December 8th 2017

Multiple Myeloma: Second Relapse and Beyond

December 8th 2017

Multiple Myeloma: Considerations in Treating Relapse

December 8th 2017

Multiple Myeloma: Using Novel Therapies at Relapse

December 8th 2017

Multiple Myeloma: Understanding and Treating Progression

December 8th 2017

Maintenance Therapy's Value in Multiple Myeloma

December 8th 2017

Multiple Myeloma: Optimizing Approaches to Transplant

December 8th 2017

The Current Role of Transplant in Multiple Myeloma

December 8th 2017

Understanding Treatment Planning in Multiple Myeloma

December 8th 2017

Strategies for Upfront Therapy in Multiple Myeloma

December 8th 2017

Multiple Myeloma: Upfront Therapy and Longer Remissions

December 8th 2017

Increasingly Improved Outcomes for Multiple Myeloma

December 8th 2017

Expert Highlights Advances in CAR T-Cell Therapy

December 5th 2017

Noelle Frey, MD, discusses the FDA approvals of CAR T-cell therapies, as well as the bright future of the treatment.

Dr. Shah on the Importance of CAR T-Cell Therapy for ALL

November 23rd 2017

Bijal D. Shah, MD, medical oncology, Moffit Cancer Center, discusses the importance of chimeric antigen receptor (CAR) T-cell therapy for patients with acute lymphoblastic leukemia (ALL).